Poly(methyl vinyl ether-co-maleic anhydride) nanoparticles as innate immune system activators

Vaccine

Volumn 29, Issue 41, 2011, Pages 7130-7135

  Camacho, A I ^a   Da Costa Martins, R ^a   Tamayo, I ^a   de Souza, J ^a   Lasarte, J J ^b   Mansilla, C ^b   Esparza, I ^a   Irache, J M ^a   Gamazo, C ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Adjuvant; Complement activation; Nanoparticles; TLR agonist

Indexed keywords

1,3 PROPANEDIAMINE; ANTIBODY; COMPLEMENT COMPONENT C3B; HYDROXYL GROUP; NANOPARTICLE; POLY(METHYL VINYL ETHER CO MALEIC ANHYDRIDE); POLYLACTIC ACID; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ADSORPTION; ANTIGEN PRESENTING CELL; ARTICLE; BIOASSAY; COMPLEMENT ACTIVATION; CONCENTRATION (PARAMETERS); CROSS LINKING; DENDRITIC CELL; DOSE RESPONSE; HUMAN; HUMAN CELL; HYDROXYLATION; IMMUNOMODULATION; INNATE IMMUNITY; LYSIS; MINIMUM INHIBITORY CONCENTRATION; PHYSICAL CHEMISTRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SHEEP ERYTHROCYTE;

ADJUVANTS, IMMUNOLOGIC; COMPLEMENT ACTIVATION; COMPLEMENT C3B; DENDRITIC CELLS; IMMUNITY, INNATE; MALEATES; NANOPARTICLES; POLYETHYLENES; PROTEIN BINDING; TOLL-LIKE RECEPTORS;

EID: 80052439788     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.072     Document Type: Article

References (38)

1. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124(4):783-801.
2. Garcon N., Chomez P., Van M.M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6(5):723-739.
3. Chu D.W., Hwang S.J., Lim F.S. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 2009, 27(52):7428-7435.
4. Krieg A.M. Toll-free vaccines?. Nat Biotechnol 2007, 25(3):303-305.
5. Tamayo I., Irache J.M., Mansilla C., Ochoa-Reparaz J., Lasarte J.J., Gamazo C. Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation. Clin Vaccine Immunol 2010, 17(9):1356-1362.
6. Sharp F.A., Ruane D., Claass B. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci USA 2009, 106(3):870-875.
7. Mann J.F., Acevedo R., Campo J.D., Perez O., Ferro V.A. Delivery systems: a vaccine strategy for overcoming mucosal tolerance?. Expert Rev Vaccines 2009, 8(1):103-112.
8. Chong C.S., Cao M., Wong W.W. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J Control Release 2005, 102(1):85-99.
9. Hamdy S., Elamanchili P., Alshamsan A., Molavi O., Satou T., Samuel J. Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(d l-lactic-co-glycolic acid) nanoparticles. J Biomed Mater Res A 2007, 81(3):652-662.
10. Raghuvanshi R.S., Katare Y.K., Lalwani K., Ali M.M., Singh O., Panda A.K. Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants. Int J Pharm 2002, 245(1-2):109-121.
11. Schlosser E., Mueller M., Fischer S. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008, 26(13):1626-1637.
12. Najar H.M., Dutz J.P. Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do. Eur J Immunol 2007, 37(8):2242-2256.
13. Mallapragada S.K., Narasimhan B. Immunomodulatory biomaterials. Int J Pharm 2008, 364(2):265-271.
14. Irache J.M., Salman H.H., Gomez S., Espuelas S., Gamazo C. Poly(anhydride) nanoparticles as adjuvants for mucosal vaccination. Front Biosci 2009.
15. Gomez S., Gamazo C., Roman B.S., Ferrer M., Sanz M.L., Irache J.M Gantrez AN nanoparticles as an adjuvant for oral immunotherapy with allergens. Vaccine 2007, 25(29):5263-5271.
16. Ochoa J., Irache J.M., Tamayo I., Walz A., DelVecchio V.G., Gamazo C. Protective immunity of biodegradable nanoparticle-based vaccine against an experimental challenge with Salmonella Enteritidis in mice. Vaccine 2007, 25(22):4410-4419.
17. Gomez S., Gamazo C., San R.B., Vauthier C., Ferrer M., Irachel J.M. Development of a novel vaccine delivery system based on Gantrez nanoparticles. J Nanosci Nanotechnol 2006, 6(9-10):3283-3289.
18. Arbos P., Campanero M.A., Arangoa M.A., Renedo M.J., Irache J.M. Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties. J Control Release 2003, 89(1):19-30.
19. Ojer P, Da Costa MR, Calvo J, Spray-drying of poly(anhydride) nanoparticles for drug/antigen delivery. Ref Type: Unpublished Work; 2010.
20. Blanco-Prieto M., Lecaroz C., Renedo M., Kunkova J., Gamazo C. In vitro evaluation of gentamicin released from microparticles. Int J Pharm 2002, 242(1-2):203-206.
21. Arbos P., Wirth M., Arangoa M.A., Gabor F., Irache J.M. Gantrez AN as a new polymer for the preparation of ligand-nanoparticle conjugates. J Control Release 2002, 83(3):321-330.
22. Seong S.Y., Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004, 4(6):469-478.
23. Kipper M.J., Wilson J.H., Wannemuehler M.J., Narasimhan B. Single dose vaccine based on biodegradable polyanhydride microspheres can modulate immune response mechanism. J Biomed Mater Res A 2006, 76(4):798-810.
24. Agueros M., Areses P., Campanero M.A. Bioadhesive properties and biodistribution of cyclodextrin-poly(anhydride) nanoparticles. Eur J Pharm Sci 2009, 37(3-4):231-240.
25. Salman H.H., Irache J.M., Gamazo C. Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination. Vaccine 2009, 27(35):4784-4790.
26. Salman H.H., Gamazo C., Campanero M.A., Irache J.M. Salmonella-like bioadhesive nanoparticles. J Control Release 2005, 106(1-2):1-13.
27. Feili-Hariri M., Falkner D.H., Morel P.A. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy. J Leukoc Biol 2005, 78(3):656-664.
28. Jenkins S.J., Hewitson J.P., Ferret-Bernard S., Mountford A.P. Schistosome larvae stimulate macrophage cytokine production through TLR4-dependent and -independent pathways. Int Immunol 2005, 17(11):1409-1418.
29. Flo T.H., Ryan L., Latz E. Involvement of toll-like receptor (TLR) 2 and TLR4 in cell activation by mannuronic acid polymers. J Biol Chem 2002, 277(38):35489-35495.
30. Xu R., Jiang Z.H. Synthesis of beta-(1→4)-oligo-d-mannuronic acid neoglycolipids. Carbohydr Res 2008, 343(1):7-17.
31. Govindaraj R.G., Manavalan B., Lee G., Choi S. Molecular modeling-based evaluation of hTLR10 and identification of potential ligands in Toll-like receptor signaling. PLoS One 2010, 5(9):e12713.
32. Kemper C., Atkinson J.P. T-cell regulation: with complements from innate immunity. Nat Rev Immunol 2007, 7(1):9-18.
33. Kemper C., Atkinson J.P., Hourcade D.E. Properdin: emerging roles of a pattern-recognition molecule. Annu Rev Immunol 2010, 28:131-155.
34. Huong T.M., Ishida T., Harashima H., Kiwada H. The complement system enhances the clearance of phosphatidylserine (PS)-liposomes in rat and guinea pig. Int J Pharm 2001, 215(1-2):197-205.
35. Nilsson B., Ekdahl K.N., Mollnes T.E., Lambris J.D. The role of complement in biomaterial-induced inflammation. Mol Immunol 2007, 44(1-3):82-94.
36. Sim R.B., Twose T.M., Paterson D.S., Sim E. The covalent-binding reaction of complement component C3. Biochem J 1981, 193(1):115-127.
37. Reddy S.T., van der Vlies A.J., Simeoni E., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007, 25(10):1159-1164.
38. Hajishengallis G., Lambris J.D. Crosstalk pathways between Toll-like receptors and the complement system. Trends Immunol 2010, 31(4):154-163.